NEW YORK (GenomeWeb) – Luminex today announced it has signed a distribution and supply agreement with Bio-Techne that will last through 2020.

Under the terms of the agreement, Bio-Techne will distribute Luminex instruments, including the Luminex 200, Flexmap 3D, and Magpix, in major markets worldwide. Bio-Techne will also continue to develop and commercialize immunoassays for the Luminex platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.